<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; direct</title>
	<atom:link href="http://www.tapanray.in/tag/direct/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>With Changing Customer Behavior Pharma To Leverage AI For Better Engagement</title>
		<link>http://www.tapanray.in/with-changing-customer-behavior-pharma-to-leverage-ai-for-better-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-changing-customer-behavior-pharma-to-leverage-ai-for-better-engagement</link>
		<comments>http://www.tapanray.in/with-changing-customer-behavior-pharma-to-leverage-ai-for-better-engagement/#comments</comments>
		<pubDate>Mon, 05 Apr 2021 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[deep]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[drops]]></category>
		<category><![CDATA[dynamics]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[feedback]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[learning]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[machine]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[nasal]]></category>
		<category><![CDATA[online]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[Voice]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10462</guid>
		<description><![CDATA[More than 55 million doses of Coronavirus vaccines were administered in India, reportedly, at the beginning of the last week of March 2021, in what is the world&#8217;s biggest inoculation drive. Notably, amid this mega initiative, the news media simultaneously reported that ‘India is facing a &#8230; <a href="http://www.tapanray.in/with-changing-customer-behavior-pharma-to-leverage-ai-for-better-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-changing-customer-behavior-pharma-to-leverage-ai-for-better-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Relevant Is A Pharma Brand Name To Patients?</title>
		<link>http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-relevant-is-a-pharma-brand-name-to-patients</link>
		<comments>http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/#comments</comments>
		<pubDate>Mon, 26 Feb 2018 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[Connect]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[counter]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTC]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[over]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[relevant]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8832</guid>
		<description><![CDATA[Are brand names necessary for medicines? Well – its’s a contentious issue, at least, as on date. It becomes the subject of a raging debate when the same question is slightly modified to: &#8211; Are brand names necessary for prescription &#8230; <a href="http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Big Pharma&#8217; Prowls Falter: Triggers Off Yet Another Critical Debate</title>
		<link>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-prowls-falter-triggers-off-yet-another-critical-debate</link>
		<comments>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/#comments</comments>
		<pubDate>Mon, 25 Nov 2013 00:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[council. India]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fostering]]></category>
		<category><![CDATA[French]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[negative]]></category>
		<category><![CDATA[off]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pitroda]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Professor]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sam]]></category>
		<category><![CDATA[SME]]></category>
		<category><![CDATA[sparks]]></category>
		<category><![CDATA[stricter]]></category>
		<category><![CDATA[stumbles]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[triggers]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Wharton]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[WIPO]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3101</guid>
		<description><![CDATA[The &#8216;Big Pharma&#8217; prowls faltered yet again exposing the ‘fault line’ to all, when the GSK global head honcho, a pharma icon in his own right, Sir Andrew Witty supported the pharmaceutical policy of India, while in the country earlier &#8230; <a href="http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-prowls-falter-triggers-off-yet-another-critical-debate/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma FDI Debate: Highly Opinionated, Sans Assessment of Tangible Outcomes?</title>
		<link>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes</link>
		<comments>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/#comments</comments>
		<pubDate>Mon, 18 Nov 2013 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[addition]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[asset]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[ilk]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[job]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Opinionated]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[shorn]]></category>
		<category><![CDATA[tangible]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[wage]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4217</guid>
		<description><![CDATA[In 2001, the Government of India (GoI) allowed 100 percent Foreign Direct Investments (FDI) in the pharmaceutical sector through automatic route to attract more investments for new asset creation, boost R&#38;D, new job creation and ultimately to help aligning Indian &#8230; <a href="http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma FDI: Damning Report of Parliamentary Panel, PM Vetoes&#8230;and Avoids Ruffling Feathers?</title>
		<link>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers</link>
		<comments>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/#comments</comments>
		<pubDate>Mon, 19 Aug 2013 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[addition]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[feathers]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[illusionary]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[matrix]]></category>
		<category><![CDATA[mergers]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[MNCs]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[oligopolistic]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[protectionism]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[restriction]]></category>
		<category><![CDATA[retrograde]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tweaking]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[vetoed]]></category>
		<category><![CDATA[vetoes veto]]></category>
		<category><![CDATA[wrong]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3241</guid>
		<description><![CDATA[An interesting situation emerged last week. The Parliamentary Standing Committee (PSC) on Commerce proposed a blanket ban on all FDI in brownfield pharma sector. Just two days after that, the Prime Minister of India vetoed the joint opposition of the Department &#8230; <a href="http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patent Conundrum: Ignoring India Will Just Not be Foolhardy, Not An Option Either</title>
		<link>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either</link>
		<comments>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/#comments</comments>
		<pubDate>Mon, 29 Apr 2013 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Enticing]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[exit]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foolhardy]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Lamy]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[lucrative]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[opposition]]></category>
		<category><![CDATA[option]]></category>
		<category><![CDATA[Pascal]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[post]]></category>
		<category><![CDATA[pre]]></category>
		<category><![CDATA[PwC]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[transfer]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2267</guid>
		<description><![CDATA[The recent verdict of the Supreme Court against Novartis, upholding the decision of the Indian Patent Office (IPO) against grant of patent to their cancer drug Glivec, based on Section 3(d) of the Indian Patents Act, has caused a flutter &#8230; <a href="http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Maira Committee’ delivers: Resolves 100% FDI issue in the pharma sector of India</title>
		<link>http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india</link>
		<comments>http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/#comments</comments>
		<pubDate>Mon, 17 Oct 2011 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[delivers]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Maira]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Resolves]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=187</guid>
		<description><![CDATA[On October 10, 2011, Dr Man Mohan Singh, the Prime Minister of India accepted the recommendation of the ‘Maira Committee’ on Foreign Direct Investment (FDI) in the Pharmaceutical Sector of India and decided that the Competition Commission of India (CCI) &#8230; <a href="http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDI in ‘Brownfield’ Pharma acquisitions and the growth of ‘Greenfield’ projects in India</title>
		<link>http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india</link>
		<comments>http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/#comments</comments>
		<pubDate>Sat, 17 Sep 2011 00:30:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[49%]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Greenfield]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[projects]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=200</guid>
		<description><![CDATA[Just when global multinational companies are inking deals to get more and more drugs manufactured in India, because of various financial and other considerations, giving a fillip to the domestic manufacturing capacity, recent media reports are carrying news items expressing &#8230; <a href="http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Credible role of CCI and NPPA should allay fear of possible ill effects of FDI in Pharmaceuticals</title>
		<link>http://www.tapanray.in/credible-role-of-cci-and-nppa-should-allay-fear-of-possible-ill-effects-of-fdi-in-pharmaceuticals/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=credible-role-of-cci-and-nppa-should-allay-fear-of-possible-ill-effects-of-fdi-in-pharmaceuticals</link>
		<comments>http://www.tapanray.in/credible-role-of-cci-and-nppa-should-allay-fear-of-possible-ill-effects-of-fdi-in-pharmaceuticals/#comments</comments>
		<pubDate>Sun, 07 Aug 2011 23:30:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[allay]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Credible]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[effects]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[fear]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[ill]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Possible]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=218</guid>
		<description><![CDATA[On August 3, 2011, ‘The Hindu Business Line’ reported, “Domestic drug-makers worried by side-effects of MNC buyouts.” It opined, “Acquisitions in the pharma industry came in for sharp focus, after several domestic drug-makers sold their operations partially or entirely to &#8230; <a href="http://www.tapanray.in/credible-role-of-cci-and-nppa-should-allay-fear-of-possible-ill-effects-of-fdi-in-pharmaceuticals/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/credible-role-of-cci-and-nppa-should-allay-fear-of-possible-ill-effects-of-fdi-in-pharmaceuticals/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In the cacophony of FDI in the pharmaceutical sector of India</title>
		<link>http://www.tapanray.in/in-the-cacophony-of-fdi-in-the-pharmaceutical-sector-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-the-cacophony-of-fdi-in-the-pharmaceutical-sector-of-india</link>
		<comments>http://www.tapanray.in/in-the-cacophony-of-fdi-in-the-pharmaceutical-sector-of-india/#comments</comments>
		<pubDate>Mon, 06 Jun 2011 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cacophony]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=247</guid>
		<description><![CDATA[It is a widely accepted fact that Foreign Direct Investment (FDI) in the Pharmaceutical industry, just like in any other industry, is important for an emerging economy like India, mainly because of various important benefits that the country would derive &#8230; <a href="http://www.tapanray.in/in-the-cacophony-of-fdi-in-the-pharmaceutical-sector-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-the-cacophony-of-fdi-in-the-pharmaceutical-sector-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
